Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations
<br/><strong>Background: </strong>Pelvic inflammatory disease (PID) has been associated with ovarian cancer risk. To clarify the role of Chlamydia trachomatis and other infectious agents in the development of ovarian cancer, we evaluated the association of serologic markers with in...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2018
|
| _version_ | 1826275081540599808 |
|---|---|
| author | Trabert, B Waterboer, T Idahl, A Brenner, N Brinton, L Butt, J Coburn, S Hartge, P Hufnagel, K Inturrisi, F Lissowska, J Mentzer, A Peplonska, B Sherman, M Wills, G Woodhall, S Pawlita, M Wentzensen, N |
| author_facet | Trabert, B Waterboer, T Idahl, A Brenner, N Brinton, L Butt, J Coburn, S Hartge, P Hufnagel, K Inturrisi, F Lissowska, J Mentzer, A Peplonska, B Sherman, M Wills, G Woodhall, S Pawlita, M Wentzensen, N |
| author_sort | Trabert, B |
| collection | OXFORD |
| description | <br/><strong>Background: </strong>Pelvic inflammatory disease (PID) has been associated with ovarian cancer risk. To clarify the role of Chlamydia trachomatis and other infectious agents in the development of ovarian cancer, we evaluated the association of serologic markers with incident ovarian cancer using a staged approach in two independent populations.<br/><strong>Methods: </strong>Studies included: 1) a case–control study in Poland (244 ovarian cancers/556 control subjects) and 2) a prospective nested case–control study in the PLCO Cancer Screening Trial (160 ovarian cancers/159 control subjects). Associations of serologic marker levels with ovarian cancer risk at diagnostic as well as higher thresholds, identified in Poland and independently evaluated in PLCO, were estimated using multivariable adjusted logistic regression.<br/><strong>Results: </strong>In the Polish study, antibodies (based on laboratory cut-point) against the chlamydia plasmid-encoded Pgp3 protein (serological gold standard) were associated with increased ovarian cancer risk (adjusted odds ratio [OR] ¼ 1.63, 95% confidence interval [CI] ¼ 1.20 to 2.22); when a positive result was redefined at higher levels, ovarian cancer risk was increased (cut-point 2: OR ¼ 2.00, 95% CI ¼ 1.38 to 2.89; cut-point 3 [max OR]: OR ¼ 2.19, 95% CI ¼ 1.29 to 3.73). In the prospective PLCO study, Pgp3 antibodies were associated with elevated risk at the laboratory cut-point (OR ¼ 1.43, 95% CI ¼ 0.78 to 2.63) and more stringent cut-points (cut-point 2: OR ¼ 2.25, 95% CI ¼ 1.07 to 4.71); cut-point 3: OR ¼ 2.53, 95% CI ¼ 0.63 to 10.08). In both studies, antibodies against other infectious agents measured were not associated with risk.<br/><strong>Conclusions: </strong>In two independent populations, antibodies against prior/current C. trachomatis (Pgp3) were associated with a doubling in ovarian cancer risk, whereas markers of other infectious agents were unrelated. These findings lend support for an association between PID and ovarian cancer. |
| first_indexed | 2024-03-06T22:53:16Z |
| format | Journal article |
| id | oxford-uuid:5f8369a6-6600-46ce-8bfa-d1ab6f853071 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:53:16Z |
| publishDate | 2018 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:5f8369a6-6600-46ce-8bfa-d1ab6f8530712022-03-26T17:47:25ZAntibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populationsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5f8369a6-6600-46ce-8bfa-d1ab6f853071EnglishSymplectic Elements at OxfordOxford University Press2018Trabert, BWaterboer, TIdahl, ABrenner, NBrinton, LButt, JCoburn, SHartge, PHufnagel, KInturrisi, FLissowska, JMentzer, APeplonska, BSherman, MWills, GWoodhall, SPawlita, MWentzensen, N<br/><strong>Background: </strong>Pelvic inflammatory disease (PID) has been associated with ovarian cancer risk. To clarify the role of Chlamydia trachomatis and other infectious agents in the development of ovarian cancer, we evaluated the association of serologic markers with incident ovarian cancer using a staged approach in two independent populations.<br/><strong>Methods: </strong>Studies included: 1) a case–control study in Poland (244 ovarian cancers/556 control subjects) and 2) a prospective nested case–control study in the PLCO Cancer Screening Trial (160 ovarian cancers/159 control subjects). Associations of serologic marker levels with ovarian cancer risk at diagnostic as well as higher thresholds, identified in Poland and independently evaluated in PLCO, were estimated using multivariable adjusted logistic regression.<br/><strong>Results: </strong>In the Polish study, antibodies (based on laboratory cut-point) against the chlamydia plasmid-encoded Pgp3 protein (serological gold standard) were associated with increased ovarian cancer risk (adjusted odds ratio [OR] ¼ 1.63, 95% confidence interval [CI] ¼ 1.20 to 2.22); when a positive result was redefined at higher levels, ovarian cancer risk was increased (cut-point 2: OR ¼ 2.00, 95% CI ¼ 1.38 to 2.89; cut-point 3 [max OR]: OR ¼ 2.19, 95% CI ¼ 1.29 to 3.73). In the prospective PLCO study, Pgp3 antibodies were associated with elevated risk at the laboratory cut-point (OR ¼ 1.43, 95% CI ¼ 0.78 to 2.63) and more stringent cut-points (cut-point 2: OR ¼ 2.25, 95% CI ¼ 1.07 to 4.71); cut-point 3: OR ¼ 2.53, 95% CI ¼ 0.63 to 10.08). In both studies, antibodies against other infectious agents measured were not associated with risk.<br/><strong>Conclusions: </strong>In two independent populations, antibodies against prior/current C. trachomatis (Pgp3) were associated with a doubling in ovarian cancer risk, whereas markers of other infectious agents were unrelated. These findings lend support for an association between PID and ovarian cancer. |
| spellingShingle | Trabert, B Waterboer, T Idahl, A Brenner, N Brinton, L Butt, J Coburn, S Hartge, P Hufnagel, K Inturrisi, F Lissowska, J Mentzer, A Peplonska, B Sherman, M Wills, G Woodhall, S Pawlita, M Wentzensen, N Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations |
| title | Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations |
| title_full | Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations |
| title_fullStr | Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations |
| title_full_unstemmed | Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations |
| title_short | Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations |
| title_sort | antibodies against chlamydia trachomatis and ovarian cancer risk in two independent populations |
| work_keys_str_mv | AT trabertb antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT waterboert antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT idahla antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT brennern antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT brintonl antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT buttj antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT coburns antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT hartgep antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT hufnagelk antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT inturrisif antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT lissowskaj antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT mentzera antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT peplonskab antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT shermanm antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT willsg antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT woodhalls antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT pawlitam antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations AT wentzensenn antibodiesagainstchlamydiatrachomatisandovariancancerriskintwoindependentpopulations |